Učitavanje...
Afatinib in advanced pretreated non-small-cell lung cancer— a Canadian experience
BACKGROUND: Afatinib, an irreversible epidermal growth factor receptor tyrosine kinase inhibitor (egfr tki), is approved for first-line therapy in advanced EGFR mutation–positive non-small-cell lung cancer (nsclc) and has previously demonstrated activity after failure of chemotherapy and reversible...
Spremljeno u:
| Izdano u: | Curr Oncol |
|---|---|
| Glavni autori: | , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Multimed Inc.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6209553/ https://ncbi.nlm.nih.gov/pubmed/30464688 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.25.3914 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|